Terms: = Ovarian cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
6 results:
1. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
2. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous ovarian cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract] [Full Text] [Related]
3. A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells.
Cheng FH; Aguda BD; Tsai JC; Kochańczyk M; Lin JM; Chen GC; Lai HC; Nephew KP; Hwang TW; Chan MW
PLoS One; 2014; 9(12):e116050. PubMed ID: 25545504
[TBL] [Abstract] [Full Text] [Related]
4. cd117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.
Huang R; Wu D; Yuan Y; Li X; Holm R; Trope CG; Nesland JM; Suo Z
PLoS One; 2014; 9(11):e112209. PubMed ID: 25380303
[TBL] [Abstract] [Full Text] [Related]
5. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Wimberger P; Roth C; Pantel K; Kasimir-Bauer S; Kimmig R; Schwarzenbach H
Int J Cancer; 2011 Jun; 128(11):2572-80. PubMed ID: 20715113
[TBL] [Abstract] [Full Text] [Related]
6. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
